JP Morgan Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph has maintained a Neutral rating on Recursion Pharmaceuticals (NASDAQ:RXRX) but has lowered the price target from $11 to $10.
November 13, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan has maintained a Neutral rating on Recursion Pharmaceuticals but reduced the price target from $11 to $10.
The reduction in price target by a major analyst like JP Morgan could lead to a negative perception among investors, potentially causing a short-term dip in the stock price of Recursion Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100